Microsatellite Instability and Immunohistochemistry Testing for Lynch Syndrome and Sporadic Colorectal Cancers

Background

Microsatellites are short, repetitive DNA sequences that are prone to errors during DNA replication, particularly in the setting of abnormal DNA mismatch repair (MMR). Microsatellite instability (MSI) is characterized by alterations in the length of these sequences. It indicates a failure to repair certain errors during DNA replication and serves as a marker of a deficiency in at least one of the DNA mismatch repair proteins. Combined analysis of MSI and immunohistochemistry (IHC) for DNA MMR protein expression provides a sensitive and specific method for identifying tumors with defects in the DNA mismatch repair complex.

Clinical Indications

Lynch Syndrome Screening

Lynch syndrome (LS) is an autosomal dominant hereditary cancer syndrome that predisposes patients to colorectal, uterine, gastric, ovarian and other tumors. It is caused by germline mutations in the mismatch repair genes MLH1, MSH2, MSH6 and PMS2, as well as germline deletions in EPCAM. At least 90% of Lynch syndrome patients can be detected through MMR testing (MSI or IHC).

In 1999, the Amsterdam II Criteria were published (see below) to identify individuals who may have Lynch syndrome:

- Three or more family members diagnosed with an HNPCC-related cancer (colorectal, endometrial, stomach, small intestine, hepatobiliary, renal pelvic or ureteral), one of whom is a first-degree relative of the other two
- Two successive affected generations
- One or more of the HNPCC-related cancers diagnosed before age 50 years
- Familial adenomatous polyposis has been excluded

In 2009, the Evaluation of Genomic Applications in Practice and Prevention recommended that all colorectal cancers undergo MSI and/or IHC testing. This recommendation was also more recently made in 2014 by the U.S. Multi-Society Task Force on Colorectal Cancer. At Cleveland Clinic, all surgically resected colorectal cancers (except those related to inflammatory bowel disease or polyposis) undergo MSI testing.

Prognostic/Predictive Role

Testing for MSI has clinical relevance in predicting responsiveness to chemotherapy. A landmark study by Ribic, et al., showed that patients with stage II and stage III colorectal carcinomas had significantly better 5-year survival in MSI-high carcinomas over stable carcinomas, but this survival advantage was lost when patients with MSI-high carcinomas received 5-FU chemotherapy. Similarly, in a phase 2 study of patients with progressive metastatic carcinoma, the mismatch repair status of each patient’s tumor predicted the clinical benefit of pembrolizumab, an anti-programmed death 1 (PD-1) immune checkpoint inhibitor. This result indicates that MMR-deficient tumors are more responsive to PD-1 blockade than MMR-proficient tumors.

Accordingly, the National Comprehensive Cancer Care Network (NCCN) recommends MMR testing should also be considered for all patients with a personal history of colon or rectal cancer.

Interpretation

**MSI-High (MSI-H):** The neoplasm exhibits instability in at least 2 of the 5 microsatellites analyzed.

**MSI-Low (MSI-L):** The neoplasm exhibits instability at only 1 microsatellite locus.

**Microsatellite stable (MSS):** The neoplasm exhibits no alterations in any of the microsatellites tested.
Note: All lesions classified as MSI-H undergo immuno-histochemistry for MLH1 and MSH2 because one of these two proteins is implicated in the vast majority of MSI-H carcinomas. If MLH1 is lost, MLH1 Promoter Hypermethylation is performed. If MLH1 and MSH2 are normally expressed in the carcinoma nuclei, then IHC for PMS2 and MSH6 are tested.

Limitations of the Assay

Both MSI and IHC are imperfectly sensitive for the detection of LS/HNPCC; however, MSI is slightly more sensitive (= 5%) than IHC because not all proteins in the DNA MMR complex can be tested by IHC and non-functional proteins may be antigenically detectable by IHC.

MSI requires a relatively pure sample of tumor, and Cleveland Clinic aims for at least 50% tumor cells to be confident in the results of the analysis. A pathologist screens the slide(s) and carefully marks the most dense area of tumor for microdissection in the lab. Borderline cases (about 25-50%) will be backed up by IHC, and cases with scant carcinoma cells (less than about 25%) will only receive IHC testing.

IHC in the evaluation of MMR suffers from capricious staining. Both false-positive and false-negative results are well-documented in the literature. Loss of expression is only interpreted if the internal positive control cells (non-lesional inflammatory cells, normal epithelium or mesenchyme) retain their normal nuclear expression. In order to reduce opportunities for diagnostic errors as well as because of the slightly reduced sensitivity of IHC, Cleveland Clinic prefers to use the IHC tests as a followup to MSI testing or a backup to technically challenging cases.

Methodology

DNA is extracted from the paraffin-embedded neoplastic tissue sections and from separate non-neoplastic paraffin-embedded tissue sections or a blood sample from the patient. PCR amplification is performed using an MSI multiplex system, which includes 5 mononucleotide markers (BAT 25, BAT 26, NR 21, NR 24, and MONO 27) in addition to 2 pentanucleotide markers to confirm sample identity (Penta C and Penta D). The PCR products are analyzed by capillary gel electrophoresis. By comparing the sizes of the PCR products from normal and abnormal samples, the presence of MSI is determined by the appearance of new alleles in the lesional sample that are not present in the corresponding normal sample.

This system meets the recommendations proposed at the 2002 National Cancer Institute's workshop on HNPCC and MSI testing.7

References


### Test Overview

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Microsatellite Instability (MSI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordering Mnemonic</td>
<td>MSICCT</td>
</tr>
<tr>
<td>Reference Range</td>
<td>Microsatellite stable (MSS): No instability detected in 5 microsatellites analyzed. MSI-Low: Instability detected in 1 of 5 (&lt;40%) microsatellites analyzed. MSI-High: Instability detected in 2 or more (at least 40%) microsatellites analyzed.</td>
</tr>
<tr>
<td>Specimen Requirements</td>
<td>Tumor tissue: 5–10 unstained sections of formalin-fixed, paraffin-embedded tissue on charged, unbaked slides (1–2 cm² total tumor area is ideal) OR 1 formalin-fixed paraffin block containing representative tumor tissue. Normal control tissue: 5–10 unstained sections of formalin-fixed, paraffin-embedded tissue on charged, unbaked slides (1–2 cm² total tumor area is ideal) OR 1 formalin-fixed paraffin block containing representative tumor tissue OR 5 mL peripheral blood in EDTA.</td>
</tr>
<tr>
<td>Test Ordering Information</td>
<td>Submit specimens with a Pathology Consult Requisition form. Indicate Microsatellite instability (MSI)</td>
</tr>
<tr>
<td>Billing Code</td>
<td>82447</td>
</tr>
<tr>
<td>CPT Code</td>
<td>83891 x 2; 83901 x 2; 83894 x 2; 83912</td>
</tr>
</tbody>
</table>